Why Is LEGEND BIOTECH CORP ADR (LEGN) Stock Moving Today?

Why LEGN stock is up today

Legend Biotech Corp ADR (LEGN) rose 5.78% to $21.84 in afternoon trading on Monday, driven by a mix of analyst activity and broader market dynamics. The stock opened with a small gap down but quickly reversed to post a strong intraday gain. Multiple analyst firms adjusted their ratings and price targets in the past 36 hours, contributing to the stock's upward momentum.

What Happened

Three separate analyst actions were reported in the past 36 hours, each reflecting a cautious stance on the stock. Oppenheimer downgraded the stock to Perform, citing CEO and competitive concerns. TD Cowen and Barclays both reduced their price targets, with TD Cowen cutting it to $24 from $29 and Barclays lowering it to $78 from $80. These moves suggest a recalibration of expectations for Legend Biotech. Meanwhile, Morgan Stanley raised its price target to $49 and RBC Capital maintained an Outperform rating but reduced its target to $58. The mixed analyst commentary appears to have spurred a buying response from investors.

What The Data Shows

The stock opened at $20.54, slightly below the prior close of $20.65, and traded as low as $20.43 before recovering to a session high of $21.90. Volume was 1.6 million shares, which is 0.6 times the 3-month average. Over the past eight sessions, the stock has gained 5.9% from $19.05 to $20.18. Recent insider transactions include two sales totaling $171K, with the most recent filing on July 2. The stock also printed five fresh 52-week lows on August 18, indicating a volatile price environment.

What To Watch

The stock is currently unprofitable with a TTM net margin of -22.0% and a beta of 0.39. Investors will want to monitor the breadth of analyst coverage and any upcoming earnings reports for further direction.